Jordi Muntañola (Barcelona, 1978) has been the CEO of Salvat laboratories for a year. This molecular biologist from Esteve, who also held positions of responsibility at the Werfen group, has placed Salvat in the club of 100 million in turnover 12 months after initiating a major transformation to enhance the values and characteristics of a family-owned pharmaceutical company with over 70 years of history; a portfolio of its own products, with brands like the antiseptic Cristalmina, and a foundation to which it dedicates a portion of its profits. And, moreover, with great prospects, with the acceleration of the third-party production business and the launch during the first half of this year of a new product in the USA, with the prospect of marketing another next year and another in China. Always accompanied by a local partner, the formula it uses for internationalization, which has led it to be present in more than 60 countries. And without ruling out possible acquisitions, a path that the company may incorporate into the 2027-2030 strategic plan, which it expects to have ready this summer.